Previous 10 | Next 10 |
Zymergen ( ZY ) +40% on $300M buyout deal with Ginkgo. Chimerix ( CMRX ) +30% sounds alarm over current outbreak. FaZe Holdings ( FAZE ) +28% . Infrastructure and Energy Alternatives ( IEA ) +26% to buy IEA in cash-and-stock deal value...
Things can change quickly in the stock market, especially in the volatile biotech industry. In early 2020, Inovio Pharmaceuticals (NASDAQ: INO) was considered a leader in the hunt for a coronavirus vaccine. Had things gone according to plan, the stock could have ended up much like ...
Inovio Pharmaceuticals (NASDAQ: INO) was once one of the biggest coronavirus-vaccine hopefuls. The company was among the first to launch clinical trials of a vaccine candidate -- and saw its shares soar more than 700% in the first half of 2020. But when the program fell behind, inve...
Royal Bank of Canada has started off coverage on the biotech company Inovio Pharmaceuticals ( NASDAQ: INO ) with a sector perform rating issued in a research note on Tuesday. Earlier in the day, Inovio announced its plans to cutback its workforce by about 18% that will record ...
Inovio ( NASDAQ: INO ) on Tuesday said it would implement a corporate reorganization which would include a reduction in its workforce by 18% and its contractors by 86%. The biotech company said the reorganization is expected to reduce operating expenses by about 30% ov...
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients PR Newswire Changes expected to reduce operational expenses and extend the company's cash runway into third quarter of ...
Inovio was a big deal during the pandemic's hurly-burly years when all matters of COVID-related excess were de rigueur. Now in the pandemic's more endemic phase, Inovio is shrinking fast. Inovio has reasonable current liquidity; however, its lack of near-term catalysts is concerni...
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire PLYMOUTH MEETING, Pa. , July 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect pe...
Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. That morning, Inovio announced that it had tapped Michael Sumner to be its new chi...
INOVIO (NASDAQ:INO) has announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer. He will serve on the company's executive leadership team and will report to INOVIO's President and CEO, Dr. Jacqueline Shea. Dr. Sumner joins INOVIO after serving as CMO of Orex...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 PR Newswire Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Applic...
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and ...
5G leader welcomes new Chief Product Officer, Senior Vice President Sales/Service Providers and Head of Operations Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises, and SMBs, today announced...